HK1163689A1 - Methods and compositions for modulating ire1, src, and abl activity ire1src abl - Google Patents
Methods and compositions for modulating ire1, src, and abl activity ire1src ablInfo
- Publication number
- HK1163689A1 HK1163689A1 HK12104444.0A HK12104444A HK1163689A1 HK 1163689 A1 HK1163689 A1 HK 1163689A1 HK 12104444 A HK12104444 A HK 12104444A HK 1163689 A1 HK1163689 A1 HK 1163689A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- abl
- ire1src
- src
- compositions
- methods
- Prior art date
Links
- 101100452784 Caenorhabditis elegans ire-1 gene Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9717308P | 2008-09-15 | 2008-09-15 | |
PCT/US2009/056993 WO2010031056A2 (fr) | 2008-09-15 | 2009-09-15 | Procédés et compositions pour moduler l’activité ire1, src, et abl |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1163689A1 true HK1163689A1 (en) | 2012-09-14 |
Family
ID=42005819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12104444.0A HK1163689A1 (en) | 2008-09-15 | 2012-05-08 | Methods and compositions for modulating ire1, src, and abl activity ire1src abl |
Country Status (8)
Country | Link |
---|---|
US (2) | US8815885B2 (fr) |
EP (1) | EP2340248B1 (fr) |
JP (3) | JP6144873B2 (fr) |
CN (2) | CN104230901A (fr) |
AU (2) | AU2009290617B2 (fr) |
CA (1) | CA2737388C (fr) |
HK (1) | HK1163689A1 (fr) |
WO (1) | WO2010031056A2 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2737388C (fr) * | 2008-09-15 | 2017-07-11 | Peter Walter | Procedes et compositions pour moduler l'activite ire1, src, et abl |
CA3042107C (fr) | 2009-11-03 | 2023-03-07 | Fosun Orinove Pharmatech, Inc. | Inhibiteurs de l'ire-1.alpha. |
US9956236B2 (en) | 2011-02-07 | 2018-05-01 | Cornell University | Methods for increasing immune responses using agents that directly bind to and activate IRE-1 |
CA2846845C (fr) | 2011-09-02 | 2016-07-19 | Children's Medical Center Corporation | Procedes et compositions pour favoriser l'homeostasie du glucose |
EP2754659A4 (fr) * | 2011-09-05 | 2015-08-26 | Zhejiang Hisun Pharm Co Ltd | Dérivés 4-substitué-(3-substitué-1h-pyrazole-5-amino)-pyrimidines ayant une activité d'inhibition de protéine kinase et son utilisation |
US20150018406A1 (en) | 2012-03-09 | 2015-01-15 | Cornell University | Modulation of breast cancer growth by modulation of xbp1 activity |
EP2999472B1 (fr) | 2013-05-22 | 2020-07-22 | The Regents of The University of California | Inhibiteurs d'aurora kinase |
DK3049521T3 (en) | 2013-09-25 | 2019-04-23 | Univ Cornell | Compounds for inducing antitumor immunity and methods thereof |
WO2015178770A1 (fr) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions pour le traitement du cancer |
WO2016022839A1 (fr) * | 2014-08-06 | 2016-02-11 | The Regents Of The University Of California | Modulateurs d'ire1 |
CN106162913B (zh) * | 2015-04-21 | 2020-09-22 | 索尼公司 | 频谱协调装置和方法、无线通信系统中的装置和方法 |
WO2018138358A1 (fr) * | 2017-01-30 | 2018-08-02 | Université de Liège | Inhibiteurs de perk et d'ire-1a contre des troubles neurodéveloppementaux |
AR111281A1 (es) | 2017-03-17 | 2019-06-26 | Genentech Inc | Compuestos de pirimidinil-piridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 |
TWI831829B (zh) * | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
JP7098826B2 (ja) | 2018-09-12 | 2022-07-11 | ジェネンテック, インコーポレイテッド | ピリミジニル-ヘテロアリールオキシ-ナフチル化合物および使用方法 |
TWI748317B (zh) | 2019-01-03 | 2021-12-01 | 美商建南德克公司 | 吡啶并-嘧啶酮與喋啶酮化合物及使用方法 |
EP3927433A1 (fr) | 2019-02-18 | 2021-12-29 | Genentech, Inc. | Composés de pyrido-pyrimidinyle et procédés d'utilisation |
WO2020232403A1 (fr) * | 2019-05-15 | 2020-11-19 | Cornell University | Traitement de la fibrose par des petites molécules inhibitrices d'ire1 |
KR102215967B1 (ko) * | 2019-05-28 | 2021-02-16 | 연세대학교 산학협력단 | IRE1α 키나아제 활성화제를 유효성분으로 포함하는 단백질 형태 이상 질환의 예방 또는 치료용 조성물 |
WO2020252165A1 (fr) | 2019-06-11 | 2020-12-17 | Genentech, Inc. | Composés quinazolinyles et procédés d'utilisation |
CN113966217A (zh) * | 2019-06-14 | 2022-01-21 | 达萨玛治疗公司 | Sarm1抑制剂 |
WO2022104151A1 (fr) * | 2020-11-13 | 2022-05-19 | The Regents Of The University Of California | Inhibiteurs de ire1alpha et utilisations associées |
CN116710429A (zh) * | 2020-11-13 | 2023-09-05 | 加利福尼亚大学董事会 | IRE1α抑制剂及其用途 |
CN112616776B (zh) * | 2021-01-04 | 2022-04-29 | 王涛 | 脊髓亚急性联合变性病模型的制备方法 |
CN114907350B (zh) * | 2021-02-10 | 2023-12-29 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物、制备方法和用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
CN1429222A (zh) | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
CA2422371C (fr) | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Composes de pyrazole utiles comme inhibiteurs de proteine kinase |
US20030105090A1 (en) * | 2000-12-21 | 2003-06-05 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
WO2003026665A1 (fr) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Derives de 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine en tant qu'inhibiteurs de la kinase, notamment, des inhibiteurs de la kinase src |
JP5208516B2 (ja) * | 2004-12-30 | 2013-06-12 | エグゼリクシス, インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
EP1746096A1 (fr) * | 2005-07-15 | 2007-01-24 | 4Sc Ag | Analogues de 2-arylbenzothiazole utiles comme agents anticancereux |
US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
CA2737388C (fr) | 2008-09-15 | 2017-07-11 | Peter Walter | Procedes et compositions pour moduler l'activite ire1, src, et abl |
WO2011047384A2 (fr) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Procédés d'inhibition de l'activité ire1 |
JP5956597B2 (ja) | 2011-11-10 | 2016-07-27 | アプリックスAplix | フックファスナー |
-
2009
- 2009-09-15 CA CA2737388A patent/CA2737388C/fr active Active
- 2009-09-15 AU AU2009290617A patent/AU2009290617B2/en not_active Ceased
- 2009-09-15 WO PCT/US2009/056993 patent/WO2010031056A2/fr active Application Filing
- 2009-09-15 EP EP09813799.5A patent/EP2340248B1/fr active Active
- 2009-09-15 CN CN201410379459.7A patent/CN104230901A/zh active Pending
- 2009-09-15 CN CN200980145225.3A patent/CN102264728B/zh active Active
- 2009-09-15 US US13/119,162 patent/US8815885B2/en active Active
- 2009-09-15 JP JP2011527045A patent/JP6144873B2/ja active Active
-
2012
- 2012-05-08 HK HK12104444.0A patent/HK1163689A1/xx not_active IP Right Cessation
-
2014
- 2014-07-02 US US14/322,765 patent/US9382230B2/en active Active
- 2014-08-14 JP JP2014165200A patent/JP2015017099A/ja not_active Withdrawn
-
2015
- 2015-08-10 AU AU2015210470A patent/AU2015210470A1/en not_active Abandoned
-
2017
- 2017-03-06 JP JP2017041213A patent/JP6412968B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2012502916A (ja) | 2012-02-02 |
US9382230B2 (en) | 2016-07-05 |
US20110319436A1 (en) | 2011-12-29 |
CN104230901A (zh) | 2014-12-24 |
AU2015210470A1 (en) | 2015-09-03 |
EP2340248A4 (fr) | 2012-06-20 |
AU2009290617A1 (en) | 2010-03-18 |
CA2737388C (fr) | 2017-07-11 |
JP2017160197A (ja) | 2017-09-14 |
JP6412968B2 (ja) | 2018-10-24 |
CA2737388A1 (fr) | 2010-03-18 |
CN102264728A (zh) | 2011-11-30 |
EP2340248B1 (fr) | 2017-05-31 |
CN102264728B (zh) | 2015-02-04 |
AU2009290617B2 (en) | 2015-05-14 |
WO2010031056A3 (fr) | 2010-08-05 |
US20150011575A1 (en) | 2015-01-08 |
US8815885B2 (en) | 2014-08-26 |
EP2340248A2 (fr) | 2011-07-06 |
JP2015017099A (ja) | 2015-01-29 |
WO2010031056A2 (fr) | 2010-03-18 |
JP6144873B2 (ja) | 2017-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1163689A1 (en) | Methods and compositions for modulating ire1, src, and abl activity ire1src abl | |
IL248652A0 (en) | Methods, compositions and devices for facilitating re-creation | |
IL239959A0 (en) | Compounds and methods for modulating kinases and their use | |
EP2068875A4 (fr) | Compositions et procédés destinés à moduler l'activité de la sirtuine | |
EP2203058A4 (fr) | Procédés et composés permettant la modulation de l'activité cannabinoïde | |
EP2203067A4 (fr) | Compositions et procédés utilisant des matières carbonées | |
IL219567A0 (en) | Compounds and methods for kinase modulation, and indications therefor | |
IL219418A0 (en) | Compounds and methods for kinase modulation, and indications therefor | |
EP2516438A4 (fr) | Composés et méthodes pour la modulation des kinases, et leurs indications | |
EP2304520A4 (fr) | Systèmes et procédés d'interactions collaboratrices | |
EP2432774A4 (fr) | Composés, compositions et procédés pour moduler des taux d'acide urique | |
EP2299828A4 (fr) | Compositions pour l'agriculture à faible taux d'utilisation et leurs procédés d'utilisation | |
EP2197434A4 (fr) | Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique | |
PL2129680T3 (pl) | Łączone kompozycje cząsteczek antysensownych o strukturze spinki do włosów oraz sposoby modulacji ekspresji | |
EP2235201A4 (fr) | Procédés et compositions pour le dosage de l'homocystéine | |
IL216388A0 (en) | New compounds, pharmaceutical composition and methods relating thereto | |
HK1161543A1 (zh) | 促進紅細胞生成的化合物和方法 | |
EP2164978A4 (fr) | Compositions et procédés pour moduler l'activité d'adamts13 | |
EP2114981A4 (fr) | Composes et procedes pour moduler l'expression des proteines | |
HUE047692T2 (hu) | Gyógyászati készítmények és eljárások stabilizálásukra | |
EP2313516A4 (fr) | Compositions et procédés pour moduler une activité de récepteur analogue à nod et leurs utilisations | |
EP2015782A4 (fr) | Compositions et procédés permettant de moduler l'expression des gènes | |
EP2205271A4 (fr) | Compositions et procédés pour des thérapies à base de ribonucléase | |
HK1141682A1 (en) | New compositions and methods for cell killing | |
HRP20150021T1 (en) | Phenanthrenone compounds, compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230915 |